Use our pre-submission checklist
Avoid common mistakes on your manuscript.
1 Correction to: Drugs https://doi.org/10.1007/s40265-021-01541-x
Since publication online on 12 June 2021 of this AdisInsight Report on Fuzuloparib (AiRuiYi®, 艾瑞颐; formerly fluzoparib), the agent was approved in China for the maintenance treatment of patients with recurrent platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy on 22nd June 2021 [1].
Reference
NMPA approval website https://mp.weixin.qq.com/s/uJ0hgF_72eAzNLNUGfSuPQ. Accessed 2 July 2021.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lee, A. Correction to: Fuzuloparib: First Approval. Drugs 81, 1227 (2021). https://doi.org/10.1007/s40265-021-01570-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40265-021-01570-6